Hybrid proteins which form heterodimers

(19)

(11)

EP 1 541 689 A3

(12)	EUROPEAN PATENT APPLICATION

(88)	Date of publication A3:
	21.11.2007 Bulletin 2007/47

(43)	Date of publication A2:
	15.06.2005 Bulletin 2005/24

(21)	Application number: 05004142.5

(22)	Date of filing: 20.02.1997

(51)

International Patent Classification (IPC):

C12N 15/62^(2006.01)
C07K 14/59^(2006.01)
C07K 14/72^(2006.01)
C12N 15/85^(2006.01)
A61K 38/24^(2006.01)
A61K 39/395^(2006.01)

C12N 15/16^(2006.01)
C07K 14/715^(2006.01)
C07K 16/46^(2006.01)
C12N 5/10^(2006.01)
C12N 15/13^(2006.01)

(84)	Designated Contracting States:
	AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	AL LT LV RO SI

(30)

Priority:

20.02.1996 US 11936 P

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	97906604.0 / 0894141

(71)	Applicant: Laboratoires Serono SA
	1267 Coinsins, Vaud (CH)

(72)	Inventors:
	CAMPBELL, Robert K. Wrentham, MA 02093 (US) JAMESON, Bradford A. Milton, MA 02186 (US) CHAPPEL, Scott C. Milton, MA 02186 (US)

(74)	Representative: Vossius & Partner
	Siebertstrasse 4 81675 München 81675 München (DE)

(54)	Hybrid proteins which form heterodimers

(57) A hybrid protein includes two expressed amino acid sequences forming a dimer. Each sequence contains the binding portion of an antibody light chain or heavy chain, optionally associated with an antibody heavy chain and a light chain, respectfully, or an antibody Fab domain linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.

Search report